Sanofi replaces CEO after R&D setbacks

Ashleigh Furlong & Sonja Wind / Bloomberg

Feb 12

Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines. (Feb 12): Sanofi abruptly replaced chief ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611054239"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611054239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611054239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611054239","market":"us","top_or_hot":-1,"title":"Sanofi replaces CEO after R&D setbacks","media":"Ashleigh Furlong & Sonja Wind / Bloomberg","content":"<div>\n<p>Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.  (Feb 12): Sanofi abruptly replaced chief ...</p>\n\n<a href=\"https://www.theedgesingapore.com/news/management-corporate-governance/sanofi-replaces-ceo-after-rd-setbacks?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Source Link</a>\n\n</div>\n","source":"edge_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi replaces CEO after R&D setbacks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi replaces CEO after R&D setbacks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-12 09:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.theedgesingapore.com/news/management-corporate-governance/sanofi-replaces-ceo-after-rd-setbacks?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS><strong>Ashleigh Furlong & Sonja Wind / Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.  (Feb 12): Sanofi abruptly replaced chief ...</p>\n\n<a href=\"https://www.theedgesingapore.com/news/management-corporate-governance/sanofi-replaces-ceo-after-rd-setbacks?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HUDAU","symbol_name":"Hudson Acquisition I Corp","start_time":0,"source_url":"https://www.theedgesingapore.com/news/management-corporate-governance/sanofi-replaces-ceo-after-rd-setbacks?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","article_id":"2611054239","we_media_id":null,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/management-corporate-governance/sanofi-replaces-ceo-after-rd-setbacks?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611054239","pubTimestamp":1770861299,"columns":[],"sourceInfo":{"source_id":"edge_highlight","name":"Edge"},"weMediaInfo":null,"summary":"Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.  ","collect":0,"end_time":0,"defaultTopTitle":"theedgesingapore.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HUDAU":"Hudson Acquisition I Corp","SNYNF":"Sanofi","BK4007":"制药"},"translate_title":"赛诺菲在研发挫折后更换首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"HUDAU":0.66},"content_text":"Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.  (Feb 12): Sanofi abruptly replaced chief executive officer Paul Hudson after a massive research spending boost failed to deliver rapid results, appointing Merck KGaA’s Belén Garijo to succeed him.\nHudson came under pressure as he tried to replace sales from a looming patent cliff for its top-selling asthma and skin disease drug Dupixent. The efforts didn’t succeed after a little over six years at the helm, with three key late-stage trials showing mixed or negative results last year. \n“Investors remain frustrated with the repeated R&D (research and development) failures,” said Abhishek Raval, an analyst at AlphaValue. \nSanofi shares fell as much as 1.2% in early Paris trading on Thursday. The stock has declined 21% over the past 12 months.\nGarijo’s term at Merck was ending soon and the Spanish executive knows Sanofi well, having spent 15 years there. She will “bring an increased rigor to the implementation of Sanofi’s strategy”, the drugmaker said in a statement. Her priority will be to strengthen the productivity, governance, and innovation capacity of R&D, it added. \nHudson set out an ambitious plan meant to turbo-charge new drugs to market in 2023. That strategy has not yet delivered results. In 2024 an experimental multiple sclerosis drug tolebrutinib failed a late-stage trial in a form of multiple sclerosis, and US regulators rejected it in another indication. Another experimental medicine for atopic dermatitis called amlitelimab — which investors had hoped could succeed Dupixent — has seen mixed results in trials. \n“If you’d have asked me back in 2020, will it take between five and seven years for Sanofi? I’d say absolutely not. We will go faster, we are smarter, we are stronger,” Hudson said in late January as he presented earnings results. “It was not to be the case.”\nSanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.  \n“Hudson significantly altered the company’s culture, often viewed as too rooted in its French origins, improved its global standing and set out a competitive earnings-growth profile though 2030,” said Bloomberg Intelligence analysts John Murphy and Mila Bankovskaia. “Sanofi’s earnings multiple nevertheless trailed peers and its shares underperformed though 2025 as he failed to deliver on his key targets to transform historically poor R&D productivity and find a replacement for lead drug Dupixent.” \nThere could be further management changes at Sanofi, Jefferies analyst Michael Leuchten wrote in a note. “Merck did manage to hire credible R&D operators from places like AstraZeneca,” he said. “And the way we know Garijo, once a strategy is set, she goes after it pretty relentlessly.”  \nAt Sanofi, Garijo served as the senior vice-president of global operations in Europe, where she led the integration of Genzyme after its acquisition. She took charge of German drug-to-semiconductor group Merck and clinched deals to help make pandemic vaccine ingredients. Her target of reaching EUR25 billion (US$29.7 billion or $37.5 billion) revenue by 2025 was cut short by a prolonged post-Covid slowdown, which she tried to counter with a stricter cost focus and acquisitions. \nHudson’s final day in the role will be Feb 17.\nUploaded by Tham Yek Lee","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}